ReviewCurrent neuropharmacology2025
Role of the Central Cholinergic Nervous System in Motor and Non-Motor Symptoms of Parkinson's Disease.
Review in Current neuropharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Postbiotics as a therapeutic frontier in Parkinson's disease: Insights into molecular pathways and neuroprotective effects.Metabolic brain disease · 2026Review
- Sex-specific gut microbiota and metabolite signatures in Parkinson's disease: implications for personalized therapeutics.Metabolic brain disease · 2026Review
- Retinal electrophysiological responses to dopaminergic therapy in treatment naïve Parkinson's disease.Documenta ophthalmologica. Advances in ophthalmology · 2026Article
- Indirubin and Retinoic Acid Show Binding Affinity to Monocyte Biomarker CSF3R in Parkinson's Disease.Journal of clinical laboratory analysis · 2026Article
- Targeting neuroimmune interactions: the therapeutic potential of kaempferol in immune-related central nervous system disorders.Frontiers in immunology · 2026Review
- Parkinson's disease beyond motor symptoms: a review of the validity and limitations of current classification of non-motor symptoms.Frontiers in psychiatry · 2026Review
- Therapeutic Benefits of Bioactive Compounds in Brain Disorders.Current neuropharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Parkinson's disease (PD) is a prevalent neurodegenerative disorder that is characterized by both motor and non-motor symptoms. Although dopamine agonists have been demonstrated to be efficacious in the treatment of motor symptoms, their capacity to enhance non-motor symptoms remains constrained. This suggests that additional neurotransmitter systems may be involved in the pathogenesis of PD-related symptoms. The cholinergic nervous system plays a pivotal role in the central nervous system, with various projection systems associated with diverse functions, including but not limited to learning, memory, attention, posture, balance, eye movement control, and adaptation. Nevertheless, the role of the cholinergic nervous system in the motor and non-motor impairments associated with PD remains uncertain. This review elucidates the location, projection, receptors, and effects of central cholinergic systems, as well as their role in both the motor symptoms and non-motor symptoms of PD. Additionally, it examines the crosstalk between cholinergic systems and dopaminergic systems in PD pathology. A deeper comprehension of the fundamental mechanisms of the cholinergic system in PD may facilitate the development of novel therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.